Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: APP009
MIFTS: 44

Appendix Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Appendix Adenocarcinoma

About this section

MalaCards integrated aliases for Appendix Adenocarcinoma:

Name: Appendix Adenocarcinoma 12 15 17
Mucinous Adenocarcinoma 52 71
Cystadenocarcinoma 52 71
Adenocarcinoma of the Appendix 52
Colonic Type Adenocarcinoma 52
Appendiceal Adenocarcinoma 12
Nonmucinous Adenocarcinoma 52
Adenocarcinoma of Appendix 71

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3608
NCIt 49 C7718
UMLS 71 C0007130 C0010631 C0238003
Sources

Summaries for Appendix Adenocarcinoma

About this section
NIH Rare Diseases : 52 Cancer of the appendix is very rare and is typically found incidentally during appendectomies, in about 1% of the cases. According to a report published by the National Cancer Institute, using the Surveillance, Epidemiology, and End Results (SEER) database, appendix cancer account for about 0.4% of gastrointestinal tumors . There are several subytpes. The most common is the carcinoid type (66% of the total), with cyst-adenocarcinoma accounting for 20% and adenocarcinoma accounting for 10%. Then there are the rare forms of cancers which include adenocarcinoid, signet ring, non-Hodgkin's lymphoma, ganglioneuroma, and pheochromocytoma. Benign primary tumors are mainly "mucinous epithelial neoplasms", also called adenomas, cystadenoma, and benign neoplastic mucocele. Adenocarcinoma of the appendix is a epithelial cancer of the appendix. The term 'epithelium' refers to cells that line hollow organs and glands and those that make up the outer surface of the body. Epithelial cells help to protect or enclose organs. Some produce mucus or other secretions. Types of adenocarcinoma of the appendix include mucinous adenocarcinoma, non-mucinous adenocarcinoma, and signet cell carcinoma of the appendix (which is the rarest, involving only 4% of all the subtypes of appendix cancer).

MalaCards based summary : Appendix Adenocarcinoma, also known as mucinous adenocarcinoma, is related to pancreatic serous cystadenocarcinoma and papillary cystadenocarcinoma. An important gene associated with Appendix Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are Relaxin signaling pathway and Cell surface interactions at the vascular wall. The drugs Cobalt and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include appendix, colon and lung.

Disease Ontology : 12 An appendix carcinoma that derives from epithelial cells of glandular origin.

Sources

Related Diseases for Appendix Adenocarcinoma

About this section

Diseases related to Appendix Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 663)
# Related Disease Score Top Affiliating Genes
1 pancreatic serous cystadenocarcinoma 34.0 KRT7 KRT20
2 papillary cystadenocarcinoma 33.9 KRT7 KRT20
3 ovarian mucinous adenocarcinoma 33.5 KRT7 KRT20 CDX2
4 bile duct cystadenocarcinoma 33.0 KRT7 KRT20 CEACAM5
5 mucinous adenocarcinoma 32.6 KRT7 KRT20 KRAS CEACAM5 CDX2
6 ovarian serous cystadenocarcinoma 32.3 SYP KRAS HRAS GNAS CEACAM5
7 mucinous stomach adenocarcinoma 32.2 KRT7 KRT20 CDX2
8 pseudomyxoma peritonei 31.2 KRT7 KRT20 KRAS CEACAM5 CDX2
9 anus adenocarcinoma 30.8 KRT7 CDX2
10 anal canal adenocarcinoma 30.8 KRT7 CDX2
11 papillary serous adenocarcinoma 30.7 KRT7 KRT20 KRAS CEACAM5
12 ovarian cystadenoma 30.5 KRT7 CEACAM5
13 mucinous lung adenocarcinoma 30.5 KRAS HRAS
14 urachal adenocarcinoma 30.5 KRAS GNAS CEACAM5
15 adenoma 30.4 KRT7 KRAS GNAS CDX2
16 adenosquamous colon carcinoma 30.4 KRT7 CDX2
17 ovarian germ cell teratoma 30.3 SYP KRT7
18 warthin tumor 30.3 KRT7 CEACAM5
19 endosalpingiosis 30.2 KRT7 KRAS
20 hemangioma 30.2 SYP KRT7 KRAS
21 benign mesothelioma 30.2 KRT7 CEACAM5
22 cystadenocarcinoma 30.1 KRT7 HRAS CEACAM5
23 ovarian brenner tumor 29.9 KRT7 KRT20
24 klatskin's tumor 29.9 KRT7 CEACAM5
25 sclerosing hemangioma 29.9 SYP KRT7
26 papillary adenocarcinoma 29.9 KRT7 KRAS CEACAM5
27 spindle cell carcinoma 29.9 SYP KRT7 HRAS
28 bladder adenocarcinoma 29.8 KRT7 KRT20 CDX2
29 carcinosarcoma 29.8 KRT7 KRAS HRAS
30 intrahepatic cholangiocarcinoma 29.8 KRT7 KRT20 KRAS CDX2
31 eyelid carcinoma 29.7 KRT7 KRT20
32 biliary papillomatosis 29.7 KRT7 CEACAM5 CDX2
33 descending colon cancer 29.7 KRAS CEACAM5 CDX2
34 transitional cell carcinoma 29.7 KRT7 KRT20 HRAS
35 gallbladder cancer 29.6 KRT7 KRAS CEACAM5 CDX2
36 cervical adenocarcinoma 29.6 KRT7 KRT20 CEACAM5 CDX2
37 large cell neuroendocrine carcinoma 29.5 SYP KRT7 KRT20
38 mature teratoma 29.5 SYP KRT7 KRAS CEACAM5
39 bile duct cysts 29.5 KRAS HRAS CEACAM5
40 cecum carcinoma 29.5 KRAS HRAS CEACAM5
41 eccrine papillary adenocarcinoma 29.5 SYP KRT7 CEACAM5
42 gastrointestinal carcinoma 29.4 KRT20 CEACAM5 CDX2
43 ovarian germ cell cancer 29.4 SYP KRT7 CEACAM5
44 polycystic liver disease 1 with or without kidney cysts 29.4 KRT7 KRT20 CEACAM5
45 malignant teratoma 29.4 SYP CEACAM5
46 intestinal obstruction 29.4 KRT7 KRT20 CEACAM5 CDX2
47 papilloma 29.4 KRT7 KRT20 KRAS
48 cavernous hemangioma 29.4 SYP KRT7 KRT20
49 appendiceal neoplasm 29.4 SATB2 KRT7 KRAS CEACAM5 CDX2
50 pancreatic intraductal papillary-mucinous neoplasm 29.3 KRAS HRAS GNAS CDX2

Graphical network of the top 20 diseases related to Appendix Adenocarcinoma:



Diseases related to Appendix Adenocarcinoma
Sources

Symptoms & Phenotypes for Appendix Adenocarcinoma

About this section
Sources

Drugs & Therapeutics for Appendix Adenocarcinoma

About this section

Drugs for Appendix Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Pembrolizumab Approved Phase 3 1374853-91-4
4
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
7
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
8
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
9
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
10
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
11
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
12
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
13
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
14
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
15
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
16
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
17
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
18
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
19
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
20
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
21
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
22
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
23
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
24
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
25
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
26
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
27 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
28
Camptothecin Experimental Phase 3 7689-03-4
29
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
30
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-17-8, 110-16-7 444972
31 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
32 Mitomycins Phase 3
33 Tetrahydrofolates Phase 3
34 Formyltetrahydrofolates Phase 3
35 Adjuvants, Immunologic Phase 3
36 topoisomerase I inhibitors Phase 2, Phase 3
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
38 Carotenoids Phase 3
39 Antimetabolites Phase 3
40 Calcium, Dietary Phase 2, Phase 3
41 Hormones Phase 2, Phase 3
42 Protein Kinase Inhibitors Phase 2, Phase 3
43 Hematinics Phase 3
44 Chelating Agents Phase 2, Phase 3
45 Estrogens Phase 2, Phase 3
46 Aromatase Inhibitors Phase 2, Phase 3
47 Hormone Antagonists Phase 2, Phase 3
48 Antifungal Agents Phase 2, Phase 3
49 Steroid Synthesis Inhibitors Phase 2, Phase 3
50 Estrogen Receptor Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 223)
# Name Status NCT ID Phase Drugs
1 RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
2 Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
3 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
4 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
5 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
6 Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
7 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
8 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
9 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
10 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
11 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
12 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
13 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
14 Randomized Phase III Trial of the Need for Adjuvant Chemotherapy in Stage I Epithelial Ovarian Cancer After Comprehensive Staging Surgery Recruiting NCT04063527 Phase 3 adjuvant chemotherapy
15 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
17 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
18 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
19 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
20 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
21 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
22 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
23 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
24 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
25 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
26 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
27 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
28 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen;Tamoxifen Citrate;Topotecan;Topotecan Hydrochloride;Trametinib;Trametinib Dimethyl Sulfoxide
29 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
30 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
31 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
32 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Not yet recruiting NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
33 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
34 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
35 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
36 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
37 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
38 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
39 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
40 Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
41 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
42 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
43 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
44 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
45 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
46 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
47 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
48 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
49 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
50 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxaneâ„¢) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for Appendix Adenocarcinoma

Sources

Genetic Tests for Appendix Adenocarcinoma

About this section
Sources

Anatomical Context for Appendix Adenocarcinoma

About this section

MalaCards organs/tissues related to Appendix Adenocarcinoma:

40
Appendix, Colon, Lung, Ovary, Prostate, Breast, Liver
Sources

Publications for Appendix Adenocarcinoma

About this section

Articles related to Appendix Adenocarcinoma:

(show top 50) (show all 2067)
# Title Authors PMID Year
1
Colonoscopic feature of primary adenocarcinoma of the appendix:. 52
18277025 2008
2
Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma. 61
31859434 2020
3
Diffuse calcificated infiltrations of the intrahepatic bile duct: Metastasis of mucinous adenocarcinoma. 61
31079838 2020
4
Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer? 61
31642963 2020
5
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. 61
31691872 2020
6
Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype. 61
31454429 2020
7
Long noncoding RNA HOXC-AS3 facilitates the progression of invasive mucinous adenocarcinomas of the lung via modulating FUS/FOXM1. 61
31925650 2020
8
Gastric-type gene expression and phenotype in non-terminal respiratory unit type adenocarcinoma of the lung with invasive mucinous adenocarcinoma morphology. 61
31985086 2020
9
Prognostic value of B-cell linker protein in colorectal cancer. 61
31980295 2020
10
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. 61
31943506 2020
11
A rare case of ovarian yolk sac tumour arising from mucinous adenocarcinoma in a 67-year-old woman. 61
31339396 2020
12
Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. 61
31769218 2020
13
Preoperative Radiographic Assessment Predicts Incomplete Cytoreduction in Patients with Low Grade Mucinous Adenocarcinoma of the Appendix. 61
31388776 2020
14
Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer. 61
31819162 2019
15
The role of adjuvant chemotherapy in stage II and III mucinous colon cancer. 61
31536150 2019
16
Characterization of breast lesions using diffusion kurtosis model-based imaging: An initial experience. 61
31815728 2019
17
Adjuvant Radiation Survival Benefits in Patients with Stage 1B Rectal Cancer: A Population-based Study from the Surveillance Epidemiology and End Result Database (1973-2010). 61
31938592 2019
18
Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study. 61
29984382 2019
19
Mucinous adenocarcinoma of the colon and rectum: A genomic analysis. 61
31729037 2019
20
Survival of patients with resected primary colorectal mucinous adenocarcinoma: A competing risk nomogram analysis. 61
31807175 2019
21
A mucinous adenocarcinoma of the lip with elevated serum carcinoembryonic antigen levels: a case report. 61
31828452 2019
22
Role of right hemicolectomy in patients with low-grade appendiceal mucinous adenocarcinoma. 61
31399196 2019
23
Incidence and survival trends for appendiceal mucinous adenocarcinoma: an analysis of 3237 patients in the Surveillance, Epidemiology, and End Results database. 61
31746646 2019
24
Prognosis of synchronous colorectal carcinoma compared to solitary colorectal carcinoma: a matched pair analysis. 61
31441800 2019
25
Is colorectal cancer a more aggressive disease in young patients? A population-based study from the Czech Republic. 61
31634775 2019
26
[The value of MR T2WI signal intensity related parameters for predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer]. 61
31770851 2019
27
Gastric mixed adeno-neuroendocrine carcinoma with a large cell neuroendocrine component A case reports. 61
31790369 2019
28
Impact of Referral Center Pathology Review on Diagnosis and Management of Patients With Appendiceal Neoplasms. 61
31714810 2019
29
Mucinous rectal cancer: concepts and imaging challenges. 61
30993392 2019
30
Sigmoid colon cancer presenting as complete prolapse. 61
31723051 2019
31
Adenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer. 61
31703713 2019
32
Expanding the indication of endoscopic submucosal dissection for undifferentiated early gastric cancer is safe or not? 61
31706922 2019
33
Similarities and differences in clinical and pathologic features of inflammatory bowel disease-associated colorectal cancer in China and Canada. 61
31725457 2019
34
A rare case of gastric-type mucinous adenocarcinoma in a woman with Peutz-Jeghers syndrome. 61
31777745 2019
35
Epidemiology of and prognostic factors for appendiceal carcinomas: a retrospective, population-based study. 61
31642969 2019
36
Primary Mucinous Adenocarcinoma of the Upper Eyelid in an African American Female: A Rare Clinical Entity. A Case Report and Literature Review. 61
31893180 2019
37
Right lower lobectomy for an aberrant mediastinal inferior lobar artery. 61
31786288 2019
38
Prognostic significance of perioperative chemotherapy on resectable colorectal mucinous adenocarcinoma liver metastasis. 61
31735042 2019
39
[Two Cases of Long-Term Control of Advanced Gastric Cancer Treated with>35 Cycles of Low-Dose Nab-Paclitaxel]. 61
31631141 2019
40
Prognostic Effects of Predominant Histologic Subtypes in Resected Pulmonary Adenocarcinomas 61
31525846 2019
41
A case of invasive mucinous adenocarcinoma of the lung showing stepwise progression at the primary site. 61
31472337 2019
42
Clinical and prognostic differences between surgically resected right-sided and left-sided colorectal cancer. 61
31612331 2019
43
[Clinicopathological characteristics of type 2 diabetes mellitus complicated with colorectal cancer]. 61
31630495 2019
44
Nomogram to predict overall survival and disease-specific survival with appendiceal mucinous adenocarcinoma. 61
31577727 2019
45
Recurrence of Bartholin gland mucinous adenocarcinoma managed with posterior exenteration: a case report. 61
31607196 2019
46
Cholecystoduodenal fistula caused by aggressive mucinous gallbladder carcinoma with a porcelain gallbladder. 61
30919282 2019
47
Prognoses of different pathological subtypes of colorectal cancer at different stages: A population-based retrospective cohort study. 61
31601167 2019
48
Feasibility of endoscopic treatment and predictors of lymph node metastasis in early gastric cancer. 61
31558878 2019
49
Proportion of goblet cell is associated with malignant potential in invasive mucinous adenocarcinoma of the lung. 61
31559671 2019
50
[A Case of Metastatic Mucinous Adenocarcinoma Derived from the Right Ovary to the Ileal Ureter]. 61
31697879 2019
Sources

Variations for Appendix Adenocarcinoma

About this section

Cosmic variations for Appendix Adenocarcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93760887 GNAS large intestine,appendix,carcinoma,adenocarcinoma c.2531G>A p.R844H 20:58909366-58909366 0
Sources

Expression for Appendix Adenocarcinoma

About this section
Search GEO for disease gene expression data for Appendix Adenocarcinoma.
Sources

Pathways for Appendix Adenocarcinoma

About this section

Pathways related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Relaxin signaling pathway 36
Show member pathways
 12.22 KRT20 KRAS HRAS GNAS
2
Cell surface interactions at the vascular wall 65
Show member pathways
 11.92 KRAS HRAS CEACAM5
3
Long-term potentiation 36
Show member pathways
 11.85 KRAS HRAS GNAS
4
Development EGFR signaling via small GTPases 22
Show member pathways
 11.72 KRAS HRAS GNAS
5
Serotonergic synapse 36
11.49 KRAS HRAS GNAS
6
Gap junction 36
11.08 KRAS HRAS GNAS
7
Bisphosphonate Pathway, Pharmacodynamics 60
Show member pathways
 10.99 KRAS HRAS
8
EGFR Transactivation by Gastrin 65
Show member pathways
 10.93 KRAS HRAS
9
MNAR-PELP1 and Estrogen Receptor Interaction 63
10.84 KRAS HRAS
10
CD209 (DC-SIGN) signaling 65
10.78 KRAS HRAS
11
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling 1
10.71 KRAS HRAS
12
Long-term depression 36
10.58 KRAS HRAS GNAS
13
p38MAPK events 65
10.27 KRAS HRAS
Sources

GO Terms for Appendix Adenocarcinoma

About this section

Biological processes related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to isolation stress GO:0035900 8.96 KRAS HRAS
2 regulation of long-term neuronal synaptic plasticity GO:0048169 8.8 SYP KRAS HRAS
Sources

Sources for Appendix Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....